Indirectly, given the poor discriminative value of FEV1 in our study, this reinforces the need of more sensitive outcomes to evaluate young people with CF in the future, considering that there will be more and more patients taking new generation of CFTR modulators. The gene discussed is CFTR; the disease is cystic fibrosis.